Moss, 18 February 2021
Gentian Diagnostics AS today announces that its patent application for a highly sensitive particle enhanced assay for the quantification of NT-proBNP has been published by the World Intellectual Property Organization (PCT Application No. PCT/EP2020/072720) with WIPO number: WO2021/028520. The technology described in this patent application enables Gentian to develop and commercialize anautomated and fast NT-proBNP assay for open turbidimetric clinical chemistry
platforms.
The launch of the NT-proBNP assay, a biomarker to aid in the diagnosis of congestive heart failure (CHF), is planned for 4Q 2021. The assay under development by Gentian Diagnostics will enable improvement of laboratory productivity based on higher throughput in comparison to currently used assays and contribute to the harmonization and standardization of the NT-proBNP assays.
Going forward, the Company will announce when patents are granted.
For further information, please contact:
Hilja Ibert
CEO, Gentian Diagnostics
E-mail: hilja.ibert@gentian.no
Cell Phone: +47 919 05 242
Njaal Kind
CFO, Gentian Diagnostics
E-mail: njaal.kind@gentian.no
Cell Phone. +47 919 06 525